Experienced Hematologist and Medical Oncologist Harminder Sethi, MD joins Maryland Oncology Hematology

Dr. Sethi has over 18 years of experience, specializing in targeted and biological therapy.

Maryland, 3/24/2022 – Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, has added Harminder Sethi, MD, to their hematology and medical oncology team. Dr. Sethi specializes in treatment plans that include targeted and biological therapy designed to treat the unique intricacies of each patient’s illness. “Dr. Sethi will see patients at the Hyattsville office located at 6505 Belcrest Rd, Hyattsville, MD 20782, as well as the White Oak Cancer Center at 11886 Healing Way Suite 701, Silver Spring, MD, 20904 once a week. Upon its opening, he will also see patients at the DC office located at 1140 Vamum St. NE in Washington, DC.

Dr. Sethi completed his initial medical education in India before finishing his residency at North Shore University Hospital, NY followed by a fellowship in oncology/hematology at Medstar Washington Hospital Center. During his fellowship, Dr. Sethi completed bone marrow transplant training in affiliation with the Fred Hutchinson Cancer Center in Seattle, WA, and additional oncology training with the National Heart, Blood, and Lung Institute. Dr. Sethi has ardent respect for his patients and develops treatment plans that include targeted therapy and biological therapy based on the most up-to-date national guidelines tailored to each patient’s particular circumstances and goals.

“I’m thrilled to join the team at Maryland Oncology Hematology to serve patients throughout our community,” said Dr. Sethi, hematology and medical oncologist, MOH. “Through our access to the latest technology and groundbreaking treatments, I’m happy to bring patients new hope in fighting cancer.”

“Dr. Sethi is an excellent addition to MOH,” said Joseph Haggerty, MOH Practice President. “His impressive experience in both hematology and medical oncology will provide a great benefit to the local community.”

 

To learn more or to schedule an appointment, visit MarylandOncology.com or call (301) 779-8800.

 

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,400 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

Facebooktwitterlinkedinmail

Maryland Oncology Hematology Adds Experienced Gynecologic Surgical Oncologist James Barter, MD, FACOG to White Oak Cancer Center

Dr. Barter is an accomplished surgeon and clinical researcher who will provide state-of-the-art treatments and minimally invasive surgical options to patients in the region.

Maryland, 3/15.2022 – Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, has added Dr. James Barter, MD, FACOG to their gynecologic oncology and surgical team at White Oak Cancer Center. Dr. Barter is experienced in minimally invasive surgeries and has performed more than 1,700 robotic surgeries and procedures.

Dr. Barter joins Maryland Oncology Hematology at The White Oak Cancer Center. Dr. Barters’ current interests include surgery using the Da Vincia surgical robot to assist in gynecologic surgery. He is ranked in the top 15 users worldwide for robotic gynecologic and gynecologic oncology procedures and has lectured both locally and internationally on the topic. Along with his extensive research with Dr. David Min and the HCSS research division, Dr. Barter has activated and overseen clinical trials with over 1,300 patients entered in protocols since 2006.

“I’m looking forward to partnering with Maryland Oncology Hematology to provide leading-edge, researchbased, and patient-centered care to the community,” said Dr. Barter, a gynecologic surgeon at White Oak Cancer Center. “With a firm understanding of the latest treatment advances and surgical techniques, I hope to bring patients new cancer care options.”

Dr. Barter is recognized as one of the country’s leading gynecologists by Good Housekeeping, perennially as one of the Top Doctors in the Washington, D.C. area, as well as one of only two gynecologic oncologists noted as top doctors in Northern Virginia. He is currently a clinical professor at George Washington University and director of gynecologic oncology research at Holy Cross Hospital. He received his medical degree from the University of Virginia and completed two years of internal medicine and four years of obstetrics and gynecology at Duke University Medical Center, followed by a fellowship in gynecologic oncology at the University of Alabama Medical Center. He was at Lombardi Cancer Center/ Georgetown University Medical Center for 16 years, rising to the rank of professor.

His four-year interest in the development of a serum blood test for ovarian cancer detection will soon culminate in published research involving serum proteomics. In conjunction with Holy Cross, Dr. Barter continues his interest in protocols dealing with novel approaches for ovarian cancer treatment, having received research grants.

“We’re thrilled to have Dr. Barter join our team of talented surgeons at Maryland Oncology Hematology” said Kashif Firozvi, MD, Director at White Oak Cancer Center. “His background in research and clinical trials, as well as his impressive experience in both gynecologic oncology and surgery will be of great benefits to the local community.”

White Oak Cancer Center is located at 11886 Healing Way Suite 101, Silver Spring, MD, 20904. To learn more or to schedule an appointment, visit MarylandOncology.com or call 301.343.3892.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,400 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

To be distributed to local media:

Practice: Maryland Oncology Hematology

Contact: Mark Lamplugh

Phone : 561-762-9729

Email : mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

Talking Cancer Prevention on Great Day Washington

Watch Nicholas DeMonaco, M.D on the WUSA9 talk show Great Day Washington talking about cancer prevention.

Facebooktwitterlinkedinmail

Maryland Oncology Hematology Announces Carolyn Hendricks, MD, FASCO Has Been Named to the Board of The American Society of Clinical Oncology

The ASCO’s Board of Directors is comprised of oncology leaders who are elected to positions reflecting various specialties within the oncology field.

Bethesda, MD (January 2022) — Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, announced today that medical oncologist Carolyn Hendricks, MD, FASCO has been named to the Board of The American Society of Clinical Oncology. Dr. Hendricks was elected to the Designated Community Oncologist seat and will begin a four-year term starting in June 2022.

Dr. Hendricks is a medical oncologist specializing in breast cancer genetics, screening, and treatment at Maryland Oncology Hematology. She has served on a number of ASCO committees, including as chair of the ABIM-ASCO Breast Cancer Exam Subcommittee, chair-elect of the Practice Quality Improvement Steering Group, past chair of the Government Relations Committee, and a member of Clinical Practice Committee and the Quality Training Program Steering Group, among another volunteer service. Dr. Hendricks was honored as Advocate of the Year by the Association for Clinical Oncology in 2019.

Dr. Hendricks specializes in breast cancer and is an active member of a multidisciplinary team focused on breast cancer genetics, screening, and treatment. She provides leading-edge and comprehensive treatment at the local level. Praised for her involvement in clinical trials for breast cancer, she brings knowledge and support to community groups by providing education about breast cancer.

Her greatest accomplishments include her ASCO (American Society of Clinical Oncology) volunteer activities both nationally and internationally in the area of quality cancer care. She received the prestigious ASCO Fellowship Award in June 2018. Dr. Hendricks is also known for heightening breast cancer awareness and delivering quality breast cancer care throughout her career.

“We are thrilled to congratulate Dr. Hendricks on this incredible achievement,” said Joseph M. Haggerty, M.D, Practice President at Maryland Oncology Hematology. “With her focus on promising new advancements in breast cancer treatment and her commitment to providing education throughout the community, Dr. Hendricks is integral in delivering comprehensive and expert care to our breast patients.”

Dr. Hendricks is currently seeing patients at MOH’s Bethesda location. Immediate appointments are available for newly referred patients to provide a high level of support and prompt access to care. Please call 301.424.6231 to make an appointment.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The  US Oncology Network (The Network). This collaboration unites the practice with more than 1,380 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. MOH also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

To be distributed to local media:
Practice: Maryland Oncology Hematology
Contact: Mark Lamplugh
Phone: 561-762-9729
Email: mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

Kashif Firozvi, M.D. was a guest on Great Day Washington

Kashif Firozvi, M.D. was a guest on Great Day Washington to talk about the White Oak Cancer Center.

Visit our other guest spots for Great Day Washington https://www.wusa9.com/search?q=%22Maryland+Oncology+Hematology%22

 

Facebooktwitterlinkedinmail

Maryland Oncology Hematology is a guest on Great Day Washington

Dr. Surupa Sen Gupta and Dr. Colette Magnant represented Maryland Oncology Hematology on Great Day Washington to explain the importance of screenings, self-exams, and living a healthy lifestyle for breast cancer awareness month.

 

Facebooktwitterlinkedinmail

What is a Cancer Clinical Trial?

When you or a loved one is diagnosed with cancer, learning about what a clinical trial is and deciding what treatment to pursue can be daunting. When you’ve exhausted the available cancer treatment options, whether through radiation oncology, hematology-oncology or some other specialty, it can be scary to think that’s there isn’t a treatment option left. Fortunately, clinical trials can provide hope and alternative treatment options for cancer patients who need them.

What Are Cancer Clinical Trials?

Clinical trials are the last phase in getting regulatory approval for new pharmaceutical medications, devices or protocols. After months or years of research and testing in the lab and, in many cases, on animals, human testing is needed to ensure safety and effectiveness. Clinical trials are conducted at many research institutions, hospitals, and community based clinics (or practices) around the world.

Why Clinical Trials Exist

Clinical trials exist to get new treatment options to patients. For instance, a clinical trial about investigational breast cancer treatments may lead to more successful outcomes for breast cancer surgeons and their patients. In addition to measuring safety, clinical trials can determine if a new therapy works, makes no difference or further impairs patients.

Who Benefits From Clinical Trials

Many people benefit from clinical trials. First, patients involved in clinical trials receive life-saving treatment earlier than it would normally be available. This is ideal for cancer patients who haven’t responded to approved therapies. For patients who cannot afford treatment, involvement in a clinical trial is sometimes at no cost to the patient. Second, researchers, doctors, and pharmaceutical manufacturers benefit by having humans to test their experimental cancer treatments on.

Third, no matter what the outcome of the trial, future cancer patients strongly benefit from clinical trials. If a new medication or treatment proves to be successful, future patients will be able to use it as a regular part of their treatment. If the clinical trial fails, future patients will not be exposed, and researchers can identify drugs that could provide better outcomes in the future.

How Clinical Trials Are Conducted

Human clinical trials are conducted in three different phases. Depending on the actual trial, there might be more phases. The first phase involves a small number of patients, and the primary concern is the safety or side effects of the treatment. Clinical trials do not aim to hurt people, so at first, the first phase stays small so researchers can closely monitor what happens. This phase happens after a lot of research has already been conducted in the lab, so there is less chance of a foreseeable adverse reaction.

The second phase also uses a small group of people. Instead of just focusing on safety, this phase examines how well the proposed treatment works. If the results still look promising, a third phase involves a larger number of people with less stringent guidelines. For example, if an earlier phase only allowed geriatric patients to be involved, this phase might expand the parameters to evaluate possible side effects and compare alternative treatments to see which is better for whom.

How to Participate in a Clinical Trial

For patients interested in participating in a clinical trial, the first step is to try conventional cancer treatment options, if possible. Many trials will ask what you’ve already tried. Next, patients need to find clinical trials through online databases, their oncologist or a local cancer center to see who’s eligible to participate.

Maryland Oncology Hematology currently has active clinical trials for breast cancer, lung cancer, Chronic Lymphocytic Leukemia (CLL), metastatic malignancies, multiple myeloma, supportive therapies and gastric cancers. These include clinical trials for many different stages of these cancers. To participate, you should ask your oncologist or contact Maryland Oncology Hematology directly.

Facebooktwitterlinkedinmail

What Is Head and Neck Cancer?

Head and neck cancers, as you may have guessed, affect areas of the head and neck. These cancers aren’t common (they account for about 3% of all malignant cancers in the United States). And, according to the National Cancer Institute, head and neck cancer diagnosis have been declining for decades. So have mortality rates.

Continue reading “What Is Head and Neck Cancer?”

Facebooktwitterlinkedinmail

Maryland Oncology Hematology and The US Oncology Network Welcome Cynthia Plate M.D. F.A.C.S, Specialist In Breast Surgery

Dr. Plate brings a new line of treatment services to the clinic, offering patients cutting-edge breast preservation techniques

 

Silver Spring, MD- November, 2020 Maryland Oncology Hematology, the premier provider of cancer services in the Maryland region, announced today it has added a breast surgical oncologist to the practice, enhancing the comprehensive multidisciplinary care it provides to breast patients. Cynthia Plate M.D. F.A.C.S specializes in breast surgery and has extensive training and experience in the field. MOH has been serving cancer patients in the Maryland area for over 40 years, providing patients convenient access to leading cancer experts and the most advanced cancer therapies available today.

Dr. Plate has many years of rigorous education, training, and experience focusing on breast disease and surgery, providing her with a superior understanding of breast cancer biology, genetics, and advanced oncoplastic surgical techniques and breast preservation procedures. By adding Dr. Plate to the practice, MOH’s new White Oak Cancer Center enhances its ability to offer multidisciplinary team care for all types of complex breast issues, including benign breast disease, malignancies, and management of high-risk patients. Seamless high-quality care is provided by a collaborative team of specialists in breast surgery, medical and radiation oncology, diagnostic imaging, pathology, genetic risk evaluation, and supportive care.

“Dr. Plate shares our passion of providing exceptional multidisciplinary cancer care, and we are delighted to have her join our growing practice” said Dr. Joseph Haggerty, President at Maryland Oncology Hematology. “With her focus on new surgical advancements in breast cancer treatment, Dr. Plate will be a great addition to our breast cancer team as we seek to deliver the best breast cancer treatment in the Maryland Region.”

Cynthia Plate M.D. F.A.C.S is board-certified in general surgery and is a breast care specialist. She previously worked with Adventist HealthCare Medical Group.

Dr. Plate graduated from Howard University College of Medicine and completed her internship and residency at Howard University Hospital

“Specializing in women’s breast health, I’m committed to providing my patients with exceptional and compassionate care,” said Dr. Plate. “I’m thrilled to join the MOH team where we can continue to deliver leading-edge cancer care to our community.”

Dr. Plate is currently seeing patients at MOH’s Silver Spring White Oak Cancer Center office. Timely appointments are available for newly referred patients, typically within 24 hours, to provide a high level of support and prompt access to care. Please call 301-933-3216 to make an appointment

 

About Maryland Oncology Hematology

 

Maryland Oncology Hematology is an affiliate of The US Oncology Network (The Network). This

collaboration unites MOH with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. MOH participates in clinical trials through US Oncology Research, which has played a role in more than 70 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.

 

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,200 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

 

Media Contacts:

 

Mark W Lamplugh Jr

The US Oncology Network

(561) 762-9729

mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology